Literature DB >> 30859654

Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans.

Roble G Bedolla1, Dimpy P Shah2,3,4, Shih-Bo Huang1, Robert L Reddick5, Rita Ghosh1,3,4,6, Addanki P Kumar1,4,5,6,7.   

Abstract

Published evidence shows a correlation between several molecular markers and prostate cancer (PCa) progression including in African Americans (AAs) who are disproportionately affected. Our early detection efforts led to the identification of elevated levels of antiapoptotic protein, c-FLIP and its upstream regulatory factors such as androgen receptor (AR), recepteur d'origine nantais (RON), a receptor tyrosine kinase in human prostate tumors. The primary objective of this study was to explore whether these markers play a role in racial disparities using immunohistochemistry in prostatectomy samples from a cohort of AA, Hispanic Whites (HWs), and non-Hispanic Whites (NHWs). Bivariable and multivariable logistic regression analyses were used to identify a statistical association between molecular markers, possible correlation with risk factors including race, obesity, prostate-specific antigen (PSA) and disease aggressiveness. Further, changes in the levels and expression of these molecular markers were also evaluated using human PCa cell lines. We found significantly elevated levels of RON ( P = 0.0082), AR ( P = 0.0001), c-FLIP ( P = 0.0071) in AAs compared with HWs or NHWs. Furthermore, a higher proportion of HW and NHWs had a high Gleason score (>6) but not PSA as compared to AAs ( P = 0.032). In summary, our findings suggest that PSA was important in predicting aggressive disease for the cohort overall; however, high levels of RON may play a role in predisposing AA men to develop aggressive disease. Future research is needed using large datasets to confirm these findings and to explore whether all or any of these markers could aid in race-specific stratification of patients for treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  androgen receptor; c-FLIP; prostate cancer; prostate cancer disparity; receptor tyrosine kinase

Mesh:

Substances:

Year:  2019        PMID: 30859654      PMCID: PMC6525017          DOI: 10.1002/mc.23002

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  36 in total

1.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

Review 2.  Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.

Authors:  Izhar Singh Batth; Huiyoung Yun; Addankl P Kumar
Journal:  Mol Carcinog       Date:  2015-07-08       Impact factor: 4.784

Review 3.  Prostate cancer in men of African origin.

Authors:  Kathleen F McGinley; Kae Jack Tay; Judd W Moul
Journal:  Nat Rev Urol       Date:  2015-12-31       Impact factor: 14.432

4.  Ron kinase transphosphorylation sustains MET oncogene addiction.

Authors:  Silvia Benvenuti; Luca Lazzari; Addolorata Arnesano; Giulia Li Chiavi; Alessandra Gentile; Paolo M Comoglio
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

Review 5.  Prostate cancer in black and white Americans.

Authors:  Sreekanth Reddy; Marc Shapiro; Ronald Morton; Otis W Brawley
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

6.  A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

Authors:  David Schreiber; Arpit Chhabra; Justin Rineer; Jeremy Weedon; David Schwartz
Journal:  Clin Genitourin Cancer       Date:  2015-02-21       Impact factor: 2.872

7.  Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.

Authors:  Devikala Gurusamy; Jerilyn K Gray; Peterson Pathrose; Rishikesh M Kulkarni; Fred D Finkleman; Susan E Waltz
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

8.  Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Authors:  Manonmani Ganapathy; Rita Ghosh; Xie Jianping; Xiaoping Zhang; Roble Bedolla; John Schoolfield; I-Tien Yeh; Dean A Troyer; Aria F Olumi; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

9.  Health behaviors and all-cause mortality in African American men.

Authors:  Roland J Thorpe; Shondelle M Wilson-Frederick; Janice V Bowie; Kisha Coa; Olivio J Clay; Thomas A LaVeist; Keith E Whitfield
Journal:  Am J Mens Health       Date:  2013-05-06

10.  Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.

Authors:  Huiyoung Yun; Jianping Xie; Aria F Olumi; Rita Ghosh; Addanki P Kumar
Journal:  Oncotarget       Date:  2015-05-10
View more
  3 in total

1.  Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.

Authors:  Peggi M Angel; Laura Spruill; Melanie Jefferson; Jennifer R Bethard; Lauren E Ball; Chanita Hughes-Halbert; Richard R Drake
Journal:  Prostate       Date:  2020-07-20       Impact factor: 4.104

Review 2.  Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Authors:  Hang-Ping Yao; Sreedhar Reddy Suthe; Xiang-Min Tong; Ming-Hai Wang
Journal:  Ther Adv Med Oncol       Date:  2020-05-12       Impact factor: 8.168

3.  Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer.

Authors:  Izhar Singh Batth; Shih-Bo Huang; Michelle Villarreal; Jingjing Gong; Divya Chakravarthy; Brian Keppler; Sridharan Jayamohan; Pawel Osmulski; Jianping Xie; Paul Rivas; Roble Bedolla; Michael A Liss; I-Tien Yeh; Robert Reddick; Hiroshi Miyamoto; Rita Ghosh; Addanki P Kumar
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.